Landmark Ideas Series: Dr. Rob Knight (Video Available)

Speaker: Rob Knight, PhD, at The American Gut Project

Date: March 17, 2022 at 4:00PM - 5:30PM

Talk Topic: Linking Human and Environmental Microbiomes for Health.

Rob Knight is the founding Director of the Center for Microbiome Innovation and Professor of Pediatrics and Computer Science & Engineering at UC San Diego. Before that, he was Professor of Chemistry & Biochemistry and Computer Science in the BioFrontiers Institute of the University of Colorado at Boulder, and an HHMI Early Career Scientist. He is a Fellow of the American Association for the Advancement of Science and of the American Academy of Microbiology. He was recently honored with the 2019 NIH Director’s Pioneer Award for his microbiome research. He received the 2017 Massry Prize, often considered a predictor of the Nobel. In 2015 he received the Vilceck Prize in Creative Promise for the Life Sciences. He is the author of “Follow Your Gut: The Enormous Impact of Tiny Microbes” (Simon & Schuster, 2015), coauthor of “Dirt is Good: The Advantage of Germs for Your Child’s Developing Immune System (St. Martin’s Press, 2017) and spoke at TED in 2014. His lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including the QIIME pipeline (cited over 17,000 times as of this writing) and UniFrac (cited over 7000 times including its web interface). He is co-founder of the Earth Microbiome Project, the American Gut Project, and the company Biota, Inc., which uses DNA from microbes in the subsurface to guide oilfield decisions. His work has linked microbes to a range of health conditions including obesity and inflammatory bowel disease, has enhanced our understanding of microbes in environments ranging from the oceans to the tundra, and made high-throughput sequencing techniques accessible to thousands of researchers around the world. Dr. Knight can be followed on Twitter (@knightlabnews) or on his web site http://knightlab.ucsd.edu/. 


Publications

Chen KY, Borglund EM, Postema EC, Dunn AG, Bourgeois FT. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis. Clinical trials (London, England) 2022.

Le Naour J, Sztupinszki Z, Carbonnier V, Casiraghi O, Marty V, Galluzzi L, Szallasi Z, Kroemer G, Vacchelli E. A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients. Oncoimmunology 2022.

Klann JG, Strasser ZH, Hutch MR, Kennedy CJ, Marwaha JS, Morris M, Samayamuthu MJ, Pfaff AC, Estiri H, South AM, Weber GM, Yuan W, Avillach P, Wagholikar KB, Luo Y, Omenn GS, Visweswaran S, Holmes JH, Xia Z, Brat GA, Murphy SN. Distinguishing Admissions Specifically for COVID-19 from Incidental SARS-CoV-2 Admissions: A National Retrospective EHR Study. Journal of medical Internet research 2022.